Agenus (NASDAQ:AGEN) Sets New 1-Year Low at $8.10

Agenus Inc. (NASDAQ:AGEN)’s share price hit a new 52-week low on Friday . The stock traded as low as $8.10 and last traded at $8.16, with a volume of 93931 shares trading hands. The stock had previously closed at $8.87.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on AGEN shares. B. Riley lowered their price objective on Agenus from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 18th. HC Wainwright reissued a “buy” rating and issued a $160.00 price objective on shares of Agenus in a report on Thursday, March 14th. Finally, StockNews.com upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Sunday, March 24th.

Agenus Stock Down 8.1 %

The stock has a 50 day simple moving average of $12.49 and a 200 day simple moving average of $14.70. The company has a market capitalization of $3.41 billion, a price-to-earnings ratio of -11.48 and a beta of 1.26.

Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($2.20). The business had revenue of $83.80 million during the quarter, compared to the consensus estimate of $54.21 million. As a group, analysts forecast that Agenus Inc. will post -0.41 EPS for the current year.

Insider Transactions at Agenus

In other Agenus news, insider Garo H. Armen acquired 25,000 shares of Agenus stock in a transaction dated Thursday, February 15th. The stock was acquired at an average cost of $13.00 per share, for a total transaction of $325,000.00. Following the completion of the transaction, the insider now owns 31,298 shares in the company, valued at approximately $406,874. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Agenus

Institutional investors have recently added to or reduced their stakes in the company. U.S. Capital Wealth Advisors LLC acquired a new stake in Agenus in the first quarter worth approximately $25,000. Commonwealth Equity Services LLC acquired a new stake in Agenus in the third quarter worth approximately $26,000. Creative Planning acquired a new stake in Agenus in the fourth quarter worth approximately $40,000. American Century Companies Inc. acquired a new stake in Agenus in the fourth quarter worth approximately $41,000. Finally, Sei Investments Co. acquired a new stake in Agenus in the first quarter worth approximately $28,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.